fiduxosin has been researched along with buspirone in 2 studies
| Studies (fiduxosin) | Trials (fiduxosin) | Recent Studies (post-2010) (fiduxosin) | Studies (buspirone) | Trials (buspirone) | Recent Studies (post-2010) (buspirone) |
|---|---|---|---|---|---|
| 14 | 3 | 5 | 2,096 | 351 | 382 |
| Protein | Taxonomy | fiduxosin (IC50) | buspirone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 1.75 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.024 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.323 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 2.125 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| D | Rattus norvegicus (Norway rat) | 0.12 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0266 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 4 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.077 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.286 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.016 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 2.125 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.044 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.75 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.2055 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.9811 | |
| Alpha-2A adrenergic receptor | Bos taurus (cattle) | 0.025 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.7 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.2666 | |
| Lysosomal alpha-glucosidase | Bos taurus (cattle) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fiduxosin and buspirone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for fiduxosin and buspirone
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |